Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Whether to fully subsidise the new generation weight loss drugs such as Mounjaro and Ozempic for obese Australians without ...

By itself, it’s not enough, but body mass index has years of evidence behind it and still has a place in clinical assessments ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...

Eli Lilly is seeking to end a lawsuit filed by ... And in the nearly two years that tirzepatide was in shortage, telehealth companies, medical spas and other clients of compounding pharmacies ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Eli Lilly (LLY) closed at $773.84 in the latest trading session, marking a -1.19% move from the prior day. The stock's change was less than the S&P 500's daily loss of 1.07%. At the same time, the Dow ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...